Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of DA-7218 in Healthy Male Volunteers
NCT02097043Phase 1Completed
- Sponsor
- Dong-A ST
- Start
- May 2014
- Primary completion
- May 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of tedizolid in acute bacterial skin and skin structure infections (ABSSSI) (6 arms), sponsored by Dong-A ST. Primary endpoints: Area Under the Concentration-Time Curve from Time Zero to Last Quantifiable Concentration at 72 hours and Maximum Plasma Concentration at 72 hours. Started May 2014; status: completed.
02
Drugs
tedizolid
03
Conditions
acute bacterial skin and skin structure infections (ABSSSI)
Beyond the preview
Go deeper on NCT02097043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02097043.